Project/Area Number |
23590641
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Applied pharmacology
|
Research Institution | Nagasaki University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
IWAO Masatomo 長崎大学, 工学部, 教授 (00100892)
上平 憲 長崎大学, 医歯(薬)学総合研究科, 教授 (80108290)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Keywords | 抗HTLV-1薬 / 分子標的治療薬 / 成人T細胞白血病 / 新規抗がん剤 / 抗ウィルス薬 |
Research Abstract |
Lamellarins, a family of hexacyclic pyrrole alkaloids originally isolated from marine invertebrates, has promising anti-tumor activity. It is also reported that lamellarin alpha 20-sulfate inhibits HIV-1 integrase. In the present study, we investigated anti-tumor activity against HTLV-1 related leukemia cell lines and activity of integrase inhibition of HTLV-1 by using new synthesis of lamellarins. We focused on an agent No.5, a new synthetics from lamellarins, that showed potent anti-tumor activity against HTLV-1 related leukemia cell lines and ATL cells but no harm to PBMCs from healthy donors. Microarray analysis indicated that unique apoptosis-related genes were up-regulated by the No.5 agent. We still continue investigating the mechanisms of apoptotic pathways as well as function of integrase inhibition caused by a new synthetics from lamellarins.
|